New smallpox vaccines for an ancient scourge

Area of Science:

• Virology
• Immunology
• Public Health Preparedness

Background:

• Variola virus, a Class A bioterrorism agent, poses a significant public health threat.
• The need for effective countermeasures against potential smallpox bioterrorism is critical.
• Existing vaccine stockpiles require ongoing evaluation for efficacy and safety.

Purpose of the Study:

• To evaluate cell culture-grown smallpox vaccines for potential use in response to bioterrorism.
• To assess the suitability of ACAM2000 and modified vaccinia Ankara (IMVAMUNE) vaccines.
• To review smallpox vaccine studies conducted at the Saint Louis University Center for Vaccine Development.

Main Methods:

• Clinical studies evaluating ACAM2000 (cell culture-grown).
• Clinical studies evaluating modified vaccinia Ankara (IMVAMUNE).
• Review of vaccine research data from the Saint Louis University Center for Vaccine Development.

Main Results:

• Data on the performance of ACAM2000 and IMVAMUNE in clinical settings.
• Assessment of vaccine candidates for national strategic stockpiles.
• Insights into the development and evaluation of smallpox countermeasures.

Conclusions:

• Cell culture-grown smallpox vaccines are under active evaluation for bioterrorism preparedness.
• ACAM2000 and IMVAMUNE are key candidates for national smallpox vaccine stockpiles.
• Ongoing research is vital for maintaining effective defenses against variola virus.